Henna Karra

Henna Karra

Auto-generated profile, based on publicly available information

Henna Karra

Department of Pathology, Pori Central Hospital, Sairaalantie 3, 28500, Pori, Finland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2014 in British Journal of Cancer
Verified
Journal Article
Open access
HKH Karra
H Karra
HRH Repo
H Repo
IAI Ahonen
I Ahonen
ELE Löyttyniemi
E Löyttyniemi
RPR Pitkänen
R Pitkänen
PKP Kronqvist
P Kronqvist
Cdc20 is an essential component of cell division and responsible for anaphase initiation regulated by securin degradation. Cdc20 function is strongly regulated by the spindle assembly checkpoint to ensure the timely separation of sister chromatids and integrity of the genome. We present the first results on Cdc20 in a large clinical breast cancer material. The study was based on 445 breast cancer patients with up to 20 years of follow-up (mean 10.0 years). DNA content was determined by image cytometry on cell imprints, and Cdc20 and securin immunohistochemistry on tissue microarrays of breast cancer tissue. In our results, high Cdc20 and securin expression was associated with aneuploid DNA content. In prognostic analyses, high Cdc20 immunoexpression alone and in combination with high securin immunoexpression indicated aggressive course of disease and up to 6.8-fold (P<0.001) risk of breast cancer death. Particularly, high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer (TNBC) subtype. We report for the first time the association of high Cdc20 and securin immunoexpression with extremely poor outcome of breast cancer patients. Our experience indicates that Cdc20 and securin are promising candidates for clinical applications in breast cancer prognostication, especially in the challenging prognostic decisions of TNBC.

27 October 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HRHeli Repo
Heli Repo
NGNatalia Gurvits
Natalia Gurvits
ELEliisa Löyttyniemi
Eliisa Löyttyniemi
MNMarjukka Nykänen
Marjukka Nykänen
MLMinnamaija Lintunen
Minnamaija Lintunen
PKPauliina Kronqvist
Pauliina Kronqvist
PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations with the clinical prognosticators and patient survival. In our material, negative PTTG1IP immunoexpression predicted a 1.5-fold risk of breast cancer death (p = 0.02). However, adding securin immunoexpression to the analysis indicated an even stronger and independent prognostic power in the patient material (HR = 2.5, p < 0.0001). The subcellular location of securin was found with potential prognostic value also among the triple-negative breast carcinomas (n = 96, p = 0.052). PTTG1IP-negativity alone and in combination with high securin immunoexpression indicates a high risk of breast cancer death, resulting in up to 14-year survival difference in our material.

19 January 2012 in Histopathology
Verified
Journal Article
Closed access
PDF file
HKHenna Karra
Henna Karra
RPReino Pitkänen
Reino Pitkänen
MNMarjukka Nykänen
Marjukka Nykänen
KTKati Talvinen
Kati Talvinen
TKTeijo Kuopio
Teijo Kuopio
PKPauliina Kronqvist
Pauliina Kronqvist